Success Metrics

Active Trials
1(17%)

Phase Distribution

Ph phase_2
1
17%
Ph phase_1
3
50%
Ph not_applicable
2
33%

Phase Distribution

3

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 2Efficacy & side effects
1(16.7%)
N/ANon-phased studies
2(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(6)

Detailed Status

Not yet recruiting5
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 13 (50.0%)
Phase 21 (16.7%)
N/A2 (33.3%)

Trials by Status

recruiting117%
not_yet_recruiting583%

Recent Activity

1 active trials
Showing 5 of 6
not_yet_recruitingnot_applicable

ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL

NCT07454226
not_yet_recruitingphase_1

Gecacitinib in the Treatment of Steroid-Refractory/Dependent Chronic Graf Versus Host Disease (cGVHD).

NCT07476872
not_yet_recruitingnot_applicable

Efficacy and Safety of Gecacitinib Hydrochloride in Prophylaxis Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis

NCT07440654
recruitingphase_1

Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer

NCT07080216
not_yet_recruitingphase_2

Study of Gecacitinib in the Treatment of Acute Graft-Versus-Host Disease After Failure of Ruxolitinib-containing Second-line Therapy

NCT07197112
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07454226Not Applicable

ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL

Not Yet Recruiting
NCT07476872Phase 1

Gecacitinib in the Treatment of Steroid-Refractory/Dependent Chronic Graf Versus Host Disease (cGVHD).

Not Yet Recruiting
NCT07440654Not Applicable

Efficacy and Safety of Gecacitinib Hydrochloride in Prophylaxis Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis

Not Yet Recruiting
NCT07080216Phase 1

Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer

Recruiting
NCT07197112Phase 2

Study of Gecacitinib in the Treatment of Acute Graft-Versus-Host Disease After Failure of Ruxolitinib-containing Second-line Therapy

Not Yet Recruiting
NCT07142837Phase 1

Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors

Not Yet Recruiting

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6